Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.
Conditions: Breast Cancer; Endocrine Therapy; CDK4/6 Inhibitors; Subsequent Treatment Intervention: Drug: Different treatment regimens following progression on CDK4/6 inhibitors. Sponsor: Hunan Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2023 Category: Research Source Type: clinical trials
Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer
Condition: Breast Cancer Female Intervention: Drug: Pyrotinib and Trastuzumab Sponsor: Youzhi Zhu Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2023 Category: Research Source Type: clinical trials
Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.
Conditions: Breast Cancer; Endocrine Therapy; CDK4/6 Inhibitors; Subsequent Treatment Intervention: Drug: Different treatment regimens following progression on CDK4/6 inhibitors. Sponsor: Hunan Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2023 Category: Research Source Type: clinical trials
Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer
Conditions: HER2-positive Breast Cancer; Early-stage Breast Cancer Interventions: Drug: pyrotinib combined with Capecitabine; Drug: treatment of physician's choice Sponsor: Peking Union Medical College Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2023 Category: Research Source Type: clinical trials
Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer
Condition: Breast Cancer Female Intervention: Drug: Pyrotinib and Trastuzumab Sponsor: Youzhi Zhu Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2023 Category: Research Source Type: clinical trials
Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer
Conditions: HER2-positive Breast Cancer; Early-stage Breast Cancer Interventions: Drug: pyrotinib combined with Capecitabine; Drug: treatment of physician's choice Sponsor: Peking Union Medical College Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2023 Category: Research Source Type: clinical trials
Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer
Condition: Breast Cancer Female Intervention: Drug: Pyrotinib and Trastuzumab Sponsor: Youzhi Zhu Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2023 Category: Research Source Type: clinical trials
Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.
Conditions: Breast Cancer; Endocrine Therapy; CDK4/6 Inhibitors; Subsequent Treatment Intervention: Drug: Different treatment regimens following progression on CDK4/6 inhibitors. Sponsor: Hunan Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 12, 2023 Category: Research Source Type: clinical trials
A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors
Condition: Her2-positive/Low-expression Urinary and Digestive Tract Tumors Intervention: Drug: BL-M07D1 Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
